---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-171957"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-06-10T23:59:59+00:00"
generated_at: "2026-06-25T02:48:10.635819+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fulcrum reports positive Phase 1b data for FTX-6058 in sickle cell disease; HbF up 6.3%

## Summary
- FTX-6058 achieved up to 6.3% increase in fetal hemoglobin (HbF) over baseline in Phase 1b trial.
- Three evaluable subjects all showed HbF increases by day 28; maximal levels may not yet be reached.
- FTX-6058 was generally well-tolerated; no serious TEAEs or discontinuations due to TEAEs.
- Company plans to complete enrollment in current and two additional dose cohorts by end of 2022, with registrational trial start in 2023.

## SEC filing metadata
- accession: 0001193125-22-171957
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312522171957/0001193125-22-171957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312522171957/d369471d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-171957
- JSON: https://secwatch.observer/filing/0001193125-22-171957.json
- Plain text: https://secwatch.observer/filing/0001193125-22-171957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.